Telix Pharmaceuticals Limited TLX
11.45
0.14
1.24%
as of 25 Sep
- Market cap
- $3.9B
- P/E
- —
Follow TLX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Dec '24 | Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+2 more quarters Free account |
2.78 | 1.33 | 1.43 | 2.01 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
38.25% | 34.45% | 39.65% | 42.29% | |
Debt/Equity |
1.02 | 0.97 | 1.11 | 1.18 | |
Asset Turnover |
— | — | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(1.79) | 0.00 | (1.20) | 0.00 | |
Intangible Assets out of Total Assets |
0.29 | 0.49 | 0.51 | 0.43 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
18.94 | (6.03) | (42.98) | 8.25 | |
Working Capital |
365.03 | 99.43 | 98.66 | 245.68 | |
Capital Expenditures |
(9.45) | (23.78) | (25.69) | (14.79) | |
Net Current Asset Value |
(17.32) | (370.00) | (418.33) | (386.15) | |
| Other line items | |||||
Quick Ratio |
2.57 | 1.11 | 1.17 | 1.71 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
— | — | 86.12 | 111.24 | |
Average Payables |
— | — | 102.32 | 112.28 | |
Average Inventory |
— | — | 24.29 | 29.67 | |
Average Assets |
— | — | 716.85 | 926.94 | |
Average Common Equity |
— | — | 257.16 | 377.07 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates